Aptose Biosciences (APTO) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APTO shares.
View APTO analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 1 year price objectives for Aptose Biosciences' stock. Their APTO share price forecasts range from $12.00 to $120.00. On average, they anticipate the company's stock price to reach $38.50 in the next year. This suggests a possible upside of 1,440.0% from the stock's current price.
View analysts price targets for APTO or view top-rated stocks among Wall Street analysts.

Aptose Biosciences' stock was trading at $8.70 at the start of the year. Since then, APTO stock has decreased by 71.3% and is now trading at $2.50.
View the best growth stocks for 2023 here.

Aptose Biosciences saw a decrease in short interest in September. As of September 15th, there was short interest totaling 29,200 shares, a decrease of 22.8% from the August 31st total of 37,800 shares. Based on an average daily volume of 39,100 shares, the short-interest ratio is currently 0.7 days. Approximately 1.3% of the company's shares are sold short.
View Aptose Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our APTO earnings forecast.

Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($2.27) earnings per share for the quarter, missing analysts' consensus estimates of ($2.09) by $0.18.

Shares of Aptose Biosciences reverse split on the morning of Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APTO stock can currently be purchased for approximately $2.50.

Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $18.25 million. The biotechnology company earns $-41,820,000.00 in net income (profit) each year or ($7.8173) on an earnings per share basis.

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120.